Live Breaking News & Updates on Phase Iii Clinical Trial
Stay updated with breaking news from Phase iii clinical trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa ....
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Ital ....
Want to move to an experimental drug that may help treat alzheimer s patients according to the long-awaited results from a phase iii clinical trial. researchers say lecanemab is one of the first drugses that can appear to show progression of cognitive decline but raise concerns of side effects. brain bleeding and swelling. the alzheimer s association said e in a statement it is encouraged by the data. joining us now, adjunct professor at the john hopkins university school of medicine, a doctor who is a senior investigators in the clinical and translational neuroscience section of the national institute on aging at the national institutes of health. ....